CD274 and non-small cell lung carcinoma: Here, we retrospectively reviewed a total of 250 cases of advanced NSCLC treated with pembrolizumab as first‐line treatment at our hospital between May 2017 and December 2019 and identified a total of four patients with high PD‐L1 expression (TPS ≥50%) who had poor PS (≥3) and were driver‐mutation negative (Table 1).